What is a typical CJC-1295 and ipamorelin dosage?

There is no established typical dose from a randomized human trial of the combination. Published CJC-1295 research used the long-acting DAC form, while human ipamorelin studies used intravenous administration. A prescriber therefore has to identify the exact formulation and concentration, review the patient’s clinical context, and write the amount, frequency and timing for that prescription.

Why are CJC-1295 and ipamorelin combined?

They act through different receptors in the growth hormone axis. CJC-1295 is a GHRH analogue, while ipamorelin is a ghrelin-receptor agonist and secretagogue. Human research shows that native ghrelin and GHRH can produce a synergistic GH response, which supports the rationale. It does not validate a CJC-1295/ipamorelin dose, because that exact pair was not tested.

Why might a prescriber time the blend near sleep?

Because growth hormone is released in pulses, and a major pulse in healthy young adults commonly follows sleep onset alongside slow-wave sleep. A prescriber may align a short-acting formulation with that window. This is physiological reasoning rather than proof of one ideal clock time, and the logic differs for long-acting CJC-1295 with DAC.

How does eating affect CJC-1295 and ipamorelin timing?

Acute glucose exposure can blunt a GHRH-stimulated growth hormone response. In one small human crossover study, oral glucose 30 minutes before intravenous GHRH reduced the mean peak GH response. No trial of the CJC-1295/ipamorelin combination established a specific fasting interval, so the meal window is part of the prescriber’s and pharmacy’s instructions.

Is CJC-1295 with DAC dosed like CJC-1295 without DAC?

No standard supports treating them as interchangeable. The DAC form binds albumin and had an estimated 5.8-to-8.1-day half-life in the principal human study. The short-acting form does not share those pharmacokinetics. Published weekly or biweekly DAC exposures therefore cannot be converted directly into a schedule for a non-DAC compounded blend.

What may a prescriber monitor during treatment?

A prescriber may use age-adjusted IGF-1 as an integrated marker of growth-hormone-axis response, alongside symptoms, tolerability and relevant metabolic measures. The exact plan depends on medical history, concurrent medications and the formulation dispensed. Because no combination trial defines one target or titration ladder, follow-up is part of dose setting rather than an optional extra.

CJC 1295 Ipamorelin Dosage: What Studies Used

CJC 1295 ipamorelin dosage has no established standard from a randomized human trial of the combination. Published studies tested the compounds separately, through different routes, and the best-known CJC-1295 trial studied the long-acting DAC form rather than the short-acting form used in many compounded blends. The useful answer is therefore not a universal number: the prescriber identifies the exact formulation, reviews the clinical context, and writes the dose and timing for that specific prescription.

This is the dosing-intent page. The CJC-1295 and ipamorelin overview covers what the blend is and how the two components act; the question here is what the literature can—and cannot—tell a prescriber.

CJC 1295 ipamorelin dosage starts with the formulation

The name CJC-1295 is used for two materially different molecules. CJC-1295 with drug affinity complex, or DAC, binds to albumin and persists for days. The short-acting form without DAC does not. A weekly exposure studied with DAC cannot be carried over to a short-acting compounded blend simply because both labels say CJC-1295.

Concentration is a separate variable. Milligrams describe the amount of peptide; milliliters describe liquid volume; syringe “units” are volume markings. The pharmacy’s concentration connects those numbers. If the concentration or vial formulation changes, the same syringe-unit number can represent a different peptide amount. That translation belongs on the prescription label.

Why a GHRH analogue and a secretagogue are combined

CJC-1295 is a growth-hormone-releasing hormone analogue. Ipamorelin is a ghrelin-receptor agonist and growth hormone secretagogue. They approach the same pituitary system through different receptors, which is the mechanistic reason clinicians sometimes pair them.

There is human evidence for the broader two-pathway idea, but not for this exact blend. In a small study of healthy men, low-dose native ghrelin given with GHRH produced a GH response greater than the summed responses to either peptide alone (Hataya et al., Journal of Clinical Endocrinology & Metabolism, 2001). That study used intravenous ghrelin and GHRH—not ipamorelin and CJC-1295. Applying its finding to this pair is a mechanistic inference, not a validated combination protocol.

What published CJC-1295 and ipamorelin protocols used

The numbers below describe study methods. They do not form one schedule, and none of the studies tested the compounded pair offered in outpatient care.

Study	Published exposure	What it actually studied
CJC-1295 in healthy adults	Single subcutaneous doses of 30, 60, 125 or 250 micrograms/kg; repeat cohorts received 20 or 30 micrograms/kg on days 0, 7 and 14, or 30 or 60 micrograms/kg on days 0 and 14	Long-acting CJC-1295 with DAC; GH, IGF-1 and pharmacokinetics—not the short-acting combination
Ipamorelin in healthy men	Five intravenous infusion levels, 4.21 to 140.45 nanomoles/kg over 15 minutes	A single-dose pharmacokinetic and GH-response experiment—not outpatient subcutaneous use
Ipamorelin after bowel surgery	0.03 mg/kg by intravenous infusion twice daily, from postoperative day 1 through day 7 or discharge	A hospital trial for postoperative ileus; it found no significant efficacy difference from placebo

In the randomized CJC-1295 studies, the estimated half-life was 5.8 to 8.1 days after a single dose, and repeated exposure produced accumulation (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). That long persistence is precisely why its dose frequency cannot validate a non-DAC schedule.

The healthy-volunteer ipamorelin study found a terminal half-life near two hours and a GH peak around 0.67 hours after the infusion (Gobburu et al., Pharmaceutical Research, 1999). A later phase 2 study used a very different intravenous regimen for a surgical gastrointestinal indication (Beck et al., International Journal of Colorectal Disease, 2014). Neither study establishes the amount, frequency or route for a CJC-1295/ipamorelin prescription.

Why meals and sleep affect timing

Bedtime timing is based on physiology, not on a trial proving a particular clock time for the blend. GH secretion is pulsatile, and in healthy young adults a major secretory episode commonly follows sleep onset in association with slow-wave sleep (Van Cauter and Copinschi, Growth Hormone & IGF Research, 2000). A prescriber may try to place a short-acting signal near that natural window. A long-acting DAC formulation remains active across many sleep and meal cycles, so the same timing logic does not transfer cleanly.

Meal separation has a physiological basis as well. In a crossover study of six healthy men, 75 g of oral glucose given 30 minutes before intravenous GHRH reduced mean peak GH from 23.70 to 8.12 ng/mL (Masuda et al., Journal of Clinical Endocrinology & Metabolism, 1985). That is evidence that acute hyperglycemia can blunt a GHRH-stimulated response. It is not evidence for a universal fasting interval: no combination trial compared morning with bedtime use, fed with fasting use, or two hours with three. The prescribed meal window therefore comes from the clinician and dispensing pharmacy.

How the prescriber arrives at a dose

The published numbers are inputs, not a ladder. A reviewing clinician has to resolve several questions before an amount can be written:

Which CJC-1295 is present? DAC status changes duration enough to change frequency logic.
What concentration will the pharmacy dispense? Dose and injection volume cannot be separated from the vial strength.
What is the baseline context? Medical history, current medications, pregnancy status, pituitary history, glucose regulation and an age-adjusted IGF-1 result may all change the decision or rule treatment out.
What will be followed? IGF-1 can show the integrated response of the GH axis, while symptoms and adverse effects determine whether continuing or adjusting remains reasonable. No combination trial supplies a universal target.
Does the response justify further exposure? CJC-1295 research showed dose-dependent and cumulative endocrine effects, so more exposure is not automatically a better decision.

At Promise, a licensed provider reviews every request and prescribes only when the blend is medically appropriate; not everyone qualifies. That clinician sets the amount, frequency, meal interval and follow-up plan rather than importing a number from a study with a different molecule or route. Related prescription options sit within hormone and organ health, but the same individualized review applies across that category.

What regulatory uncertainty adds to the decision

Promise’s CJC-1295 / ipamorelin product is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As of August 2026, the FDA’s compounding risk page says clinical data for CJC-1295 are limited and identifies potential immunogenicity and peptide-impurity concerns; for ipamorelin acetate, it says safety information is insufficient for certain injectable routes.

FDA status is not a dosing formula or a marketing gate. A licensed provider may still prescribe a compounded formulation—the decision is between the patient and the doctor—and the limited evidence is one reason that individualized review and follow-up matter.

What the prescription should make unambiguous

A complete order resolves the peptide forms, amount per dose, corresponding injection volume, timing relative to food and sleep, and the follow-up point. Those details travel together. A dose copied without the formulation and concentration is incomplete; a timing rule copied without the route and pharmacokinetics is equally so.

The narrow conclusion is the useful one: published protocols show biological activity and large differences between formulations, but they do not supply a standard combined dose. The prescription label and the reviewing clinician’s plan are the protocol for the individual patient.